{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:32:21Z","timestamp":1785850341787,"version":"3.56.0"},"reference-count":25,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Low-dose-rate (LDR) brachytherapy with I-125 seeds is one of the most common primary tumor treatments for low-risk and low-intermediate-risk prostate cancer. This report aimed to present an analysis of single-institution long-term results. We analyzed the treatment outcomes of 119 patients with low- and intermediate-risk prostate cancer treated with LDR brachytherapy at our institution between 2014 and 2020. The analysis focused on biochemical recurrence rates (BRFS), overall survival (OS), cumulative local recurrence rate (CLRR), and the incidence of acute and late toxicities. Patient-reported quality of life measures were also evaluated to provide a holistic view on the treatment\u2019s impact. The median follow-up period was 46 months. CLRR was 3.3% (4\/119), five-year BRFS was 87%, and the five-year OS rate was 95%. Dysuria was the most common acute urinary toxicity, reported in 26.0% of patients as grade 1 and 13.4% as grade 2. As a late side effect, 12.6% of patients experienced mild dysuria. Sexual dysfunction persisted in 6.7% of patients as grade 1, 7.5% as grade 2, and 10.0% as grade 3. LDR brachytherapy in patients with prostate cancer is an effective treatment, with favorable clinical outcomes and manageable toxicity. The low CLRR and high OS rates, as well as low incidence of severe side effects, support the continued use of LDR brachytherapy as a primary treatment modality for localized prostate cancer.<\/jats:p>","DOI":"10.3390\/jpm14080882","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T05:16:24Z","timestamp":1724649384000},"page":"882","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes of I-125 Low-Dose-Rate Brachytherapy in Patients with Localized Prostate Cancer: A Comprehensive Analysis from a Specialized Tertiary Referral Center"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0353-6283","authenticated-orcid":false,"given":"Philipp","family":"Schubert","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"},{"name":"CCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), 91054 Erlangen, Germany"},{"name":"BZKF: Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vratislav","family":"Strnad","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"},{"name":"CCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), 91054 Erlangen, Germany"},{"name":"BZKF: Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"H\u00f6fler","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"},{"name":"CCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), 91054 Erlangen, Germany"},{"name":"BZKF: Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1985-4116","authenticated-orcid":false,"given":"Claudia","family":"Schweizer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"},{"name":"CCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), 91054 Erlangen, Germany"},{"name":"BZKF: Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3966-2872","authenticated-orcid":false,"given":"Florian","family":"Putz","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"},{"name":"CCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), 91054 Erlangen, Germany"},{"name":"BZKF: Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lotter","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"},{"name":"CCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), 91054 Erlangen, Germany"},{"name":"BZKF: Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Kreppner","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"},{"name":"CCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), 91054 Erlangen, Germany"},{"name":"BZKF: Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Karius","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"},{"name":"CCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), 91054 Erlangen, Germany"},{"name":"BZKF: Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Fietkau","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"},{"name":"CCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), 91054 Erlangen, Germany"},{"name":"BZKF: Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricarda","family":"Merten","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"},{"name":"CCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"CCC WERA: Comprehensive Cancer Center Alliance WERA (CCC WERA), 91054 Erlangen, Germany"},{"name":"BZKF: Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: Planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.radonc.2021.12.047","article-title":"GEC-ESTRO ACROP prostate brachytherapy guidelines","volume":"167","author":"Henry","year":"2022","journal-title":"Radiother. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijrobp.2010.08.045","article-title":"American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer","volume":"79","author":"Rosenthal","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5114\/jcb.2024.135630","article-title":"Low-dose-rate brachytherapy and long-term treatment outcomes in patients younger than 60 years of age","volume":"16","author":"Armstrong","year":"2024","journal-title":"J. Contemp. Brachyther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"738","DOI":"10.21873\/invivo.13136","article-title":"Prostate-specific Antigen Levels Following Brachytherapy Impact Late Biochemical Recurrence in Japanese Patients With Localized Prostate Cancer","volume":"37","author":"Ueno","year":"2023","journal-title":"Vivo"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.prnil.2023.01.004","article-title":"The oncologic and safety outcomes of low-dose-rate brachytherapy for the treatment of prostate cancer","volume":"11","author":"Tanaka","year":"2023","journal-title":"Prostate Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.clon.2023.01.006","article-title":"Long-Term Biochemical Control of a Prospective Cohort of Prostate Cancer Patients Treated With Interstitial Brachytherapy Versus Radical Prostatectomy","volume":"35","author":"Sanmamed","year":"2023","journal-title":"Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/pros.24507","article-title":"Quality of life in patients who underwent robot-assisted radical prostatectomy compared with those who underwent low-dose-rate brachytherapy","volume":"83","author":"Nakai","year":"2023","journal-title":"Prostate"},{"key":"ref_11","first-page":"CD008871","article-title":"Low-dose rate brachytherapy for men with localized prostate cancer","volume":"7","author":"Peinemann","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Patel, M., Turchan, W.T., Morris, C.G., Augustine, D., Wu, T., Oto, A., Zagaja, G.P., and Liauw, S.L. (2023). A Contemporary Report of Low-Dose-Rate Brachytherapy for Prostate Cancer Using MRI for Risk Stratification: Disease Outcomes and Patient-Reported Quality of Life. Cancers, 15.","DOI":"10.3390\/cancers15041336"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00066-024-02222-w","article-title":"Radiotherapy in localized prostate cancer: A multicenter analysis evaluating tumor control and late toxicity after brachytherapy and external beam radiotherapy in 1293 patients","volume":"200","author":"Moll","year":"2024","journal-title":"Strahlenther. Onkol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Tsuchiya, K., Kawase, M., Nakane, K., Nakano, M., Iinuma, K., Kato, D., Takai, M., Tobisawa, Y., Mori, T., and Takano, H. (2023). Chronological Changes of Lower Urinary Tract Symptoms in Elderly Patients with Prostate Cancer after Low-Dose-Rate Prostate Brachytherapy. Life, 13.","DOI":"10.3390\/life13071507"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2003.09.015","article-title":"Quality of life following treatment for early prostate cancer: Does low dose rate (LDR) brachytherapy offer a better outcome? A review","volume":"45","author":"Henderson","year":"2004","journal-title":"Eur. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e14288","DOI":"10.1111\/and.14288","article-title":"Erectile dysfunction and sexual quality of life in patients who underwent low-dose-rate brachytherapy alone for prostate cancer","volume":"54","author":"Nakai","year":"2022","journal-title":"Andrologia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13014-017-0884-y","article-title":"Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation","volume":"12","author":"Geara","year":"2017","journal-title":"Radiat. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Combes, A.D., Palma, C.A., Calopedos, R., Wen, L., Woo, H., Fulham, M., and Leslie, S. (2022). PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer. Diagnostics, 12.","DOI":"10.3390\/diagnostics12112594"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijrobp.2024.02.064","article-title":"A Randomized Trial Comparing Quality of Life After Low-Dose Rate or High-Dose Rate Prostate Brachytherapy Boost With Pelvic External Beam Radiation Therapy","volume":"120","author":"Crook","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2007.04.011","article-title":"High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomised phase three trial","volume":"84","author":"Hoskin","year":"2007","journal-title":"Radiother. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s00066-023-02060-2","article-title":"Toxicity of dose-escalated radiotherapy up to 84 Gy for prostate cancer","volume":"199","author":"Rosenbrock","year":"2023","journal-title":"Strahlenther. Onkol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Moll, M., Magrowski, L., Mittlbock, M., Heinzl, H., Kirisits, C., Ciepal, J., Masri, O., Heilemann, G., Stando, R., and Krzysztofiak, T. (2024). Biochemical control in intermediate- and high-risk prostate cancer after EBRT with and without brachytherapy boost. Strahlenther. Onkol.","DOI":"10.1007\/s00066-024-02245-3"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.eururo.2023.09.001","article-title":"The Role of Multiparametric MRI and MRI-targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FORECAST Trial","volume":"85","author":"Light","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1007\/s00345-023-04663-x","article-title":"The march toward single-fraction stereotactic body radiotherapy for localized prostate cancer-Quo Vadimus?","volume":"41","author":"Ong","year":"2023","journal-title":"World J. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zamboglou, C., Spohn, S.K.B., Adebahr, S., Huber, M., Kirste, S., Sprave, T., Gratzke, C., Chen, R.C., Carl, E.G., and Weber, W.A. (2021). PSMA-PET\/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial. Cancers, 13.","DOI":"10.3390\/cancers13225795"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/8\/882\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:40:27Z","timestamp":1760110827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/8\/882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["jpm14080882"],"URL":"https:\/\/doi.org\/10.3390\/jpm14080882","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,21]]}}}